ERBB2 and breast carcinoma: While onco-immune co-culturing has been studied with cancer cells and TAMs, to our knowledge, the impact of T-cells on HER2 + breast cancer and subsequent longitudinal response to anti-HER2 therapy has not yet been investigated.